Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

Benzinga Newsdesk www.benzinga.com Neutral 62.1%

Neg 0% Neu 62.1% Pos 0%

Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating.

Comments

No comments yet. Be the first!